Good morning, everyone, and how are you today? The last few days here on the Pharmalot corporate campus have been eventful as the hurricane blew by us. We hope that those of you who were effected by the storm are okay and the recovery process goes as well as possible. Meanwhile, we are downing a necessary cup or two of stimulation; one more reason to boil the water, yes? And here are some items of interest. Have a good day and stay in touch...
Astellas Clot Drug Raises Bleeding In Heart Study (Reuters)
Pfizer Sells Virginia Plant To Henrico (Richmond Times-Dispatch)
Glaxo Creates A Shark Tank For Its Scientists (The Ottawa Citizen)
Ipsen Raises Sales Forecast And Names Finance Chief (Bloomberg News)
UK Biotech Stars Just Fade Away (The Guardian)
AstraZeneca Bloodthinner Shows Mortality Benefit Versus Plavix (Dow Jones)
FDA Rejects NuPathe Migraine Patch (Reuters)
Teva Says Copaxone Lawsuit Will Go To Trial (Bloomberg News)
Rheumatoid Arthritis Patients Wait Seven Years For Biologics: Study (Pharma Times)
BASF Raises API Prices By 10 Percent (Contract Pharma)
FDA Wants Risk-Based, Centralized Trial Monitoring (Outsourcing Pharma)
EDITOR’S NOTE: Please check this post for updates throughout the morning
steaming coffee thx to dleggett on flickr
4 Comments
Keep an eye on BASF and their price hike. For those who don't know, back in 1999 BASF and Roche were involved in one of the most massive price fixing scandals in the history of the pharmaceutical industry. All done on a secret mountain hideaway.
http://www.icis.com/Articles/1999/05/31/84006/roche-basf-face-european-fines-censure.html
Re: "RA Patients Wait 7 Years for Biologics" - the title was surprising, then I saw it was the result of an online market research study.
Hi Suzanne,
Thanks for writing and pointing that out. I've gone back and massaged the headline to include the word study, which should have been there in the first place. Sorry for the confusion.
Regards ed
Thanks Ed, but I wasn't trying to nitpick you. The original article omits that it was market research. You have to follow the link to see what the article described as "global pharmaceutical research agency The Research Partnership" is "a full service global market research agency dedicated to the pharma industry".
It appears this was an online survey and I'm assuming the 'researchers' were not of the clinical variety. Here's more: "Findings from the research suggest that pharmaceutical marketers working with RA brands need to do more to persuade doctors to move patients more quickly onto a biologic to improve satisfaction and prevent their condition worsening." "An attitudinal segmentation was undertaken on the findings, providing a detailed depiction of 4 distinct patient types - “Naïve Nick”, “Suffering Sarah”, “Challenging Charlie” and “Experienced Eve”."
http://www.researchpartnership.com/news